INTRODUCTION
Obsessive-compulsive disorder (OCD) is a distressing and impairing condition that affects between 0.25% and 4% of children and adolescents. 1 In 2005, the National Institute of Health and Care Excellence (NICE) introduced guidelines for the management of paediatric OCD in the UK. 2 Based on robust evidence, NICE recommended cognitive behavioural therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) as first-line psychological and pharmacological treatments. However, the extent to which patients are able to access these evidence-based interventions in routine clinical practice remains unclear.
To assess the impact of these guidelines, we conducted an audit of the previous treatment received by children with OCD referred to the National and Specialist Paediatric (N&S) OCD clinic at the Maudsley Hospital, London. We hypothesised that publication of NICE guidelines, in 2005, would increase the use of SSRIs and CBT in this group of patients.
METHODS
We compared referrals received from January 2000 to January 2002 (T1 cohort, n=79) with those from January 2009 to January 2011 (T2 cohort, n=143). All data were collected as part of the routine standardised assessment carried out in the N&S OCD clinic. Table 1 shows the baseline demographic/clinical data collected for each cohort. Treatment data were categorised into whether patients had ever previously received CBT for OCD, an SSRI medication or a non-CBT-based psychotherapy (eg, family therapy, counselling, psychodynamic therapy) or whether they had received either NICE-recommended treatment (SSRI or CBT). Contrary to our hypothesis, when comparing patients in the T2 cohort with those in the T1 cohort, we found a significant 22.3% decrease in the proportion who had received either NICE-recommended treatments (SSRI or CBT) (χ 2 (1, n=222) =10.18, p=0.001), with over half having not received either treatment. There was a significant 23.0% decrease in the proportion who had received an SSRI (χ 2 (1, n=222)=23.87, p<0.001) and no significant increase in patients receiving CBT (χ 2 (1, n=222)=0.66, p=0.418). We also found a significant 13.1% increase in the proportion of patients receiving non-CBT psychotherapy (χ 2 (1, n=222) =5.38, p=0.019).
RESULTS

DISCUSSION
Despite the publication of NICE guidelines in 2005, we found a striking decrease in SSRI use, no increase in the use of CBT, and an increase in non-CBT-based psychotherapies between our two cohorts. Shortage of CBT therapists in child services and concerns around the safety of SSRIs in this population may explain some of our findings. 3 4 Further work is urgently needed to identify the barriers preventing young people with OCD from accessing evidence-based treatments. 3 The use of such tools has increased over time and broadened to include sub-specialty locations with a higher risk of acute deterioration. 4 We undertook a case-note review of the prevalence of raised PAWS (≥3; the trigger for medical review) and clinician's responses to these in patients under the care of paediatric haematology and oncology in the Leeds Children's Hospital. A total of 140 patient observation points were randomly selected, stratified by time period and date. PAWS and clinical details were recorded for each observation point, 48 h before and after this point.
Data were available on 103 of the observation points, with 37 missing through difficulties obtaining the PAWS charts. Twenty-eight of 103 (27.2%) had a PAWS ≥3. In the 48 h before and after the time point, 63.1% and 61.8% of inpatients had a PAWS ≥3, respectively.
Nine of the patients with raised PAWS had a nursing review documented, with a medical review requested in two patients. Another patient received a medical review without documented nursing review. Four patients with a low PAWS received a medical review due to other clinical concerns.
Of the 28 patients with PAWS ≥3 at the index time point, four had an adverse event in the preceding 48 h and five had an adverse event in the following 48 h (including one patient who had an adverse event in both time frames). Eleven of the 19 recorded adverse events occurred in patients with PAWS <3. One adverse event necessitated pediatric intensive care unit admission, while the other events included new bacteraemia, administration of fluid boluses, acute renal impairment, acute right hemiplegia and medication error (see figure 1) .
We conclude that a raised PAWS does not necessarily indicate significant deterioration, noting that the majority of adverse events occurred in patients without raised PAWS. In this population, the sensitivity and specificity of a PAWS ≥3 was poor (sensitivity 0.56 (CI 0.21 to 0.86) and specificity 0.76 (CI 0.66 to 0.84)), to detect a future adverse event. We acknowledge that our review was limited by reference only to documented scores and reviews, and that the effects of the reviews apparently triggered by PAWS may have prevented other adverse events. Further consideration needs to be taken to identify the appropriate early detection systems (both the scores and interventional advice) for patients under the care of paediatric haematology and oncology, as performing the recommended interventions is not feasible or efficient with current resources. Work is ongoing within Leeds Children's Hospital to develop such a system-further evaluation will be performed following its implementation. Other subspecialties might also consider how early warning score systems could be adjusted for their populations. 
